Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14351 - 14375 of 14939 in total
Esatenolol is a beta blocker.
Experimental
Experimental
Experimental
APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. APL-9 is designed...
Investigational
Matched Description: … mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and
An anticholesteremic agent.
Experimental
Talviraline has been used in trials studying the treatment of HIV Infections.
Investigational
A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.
Withdrawn
Piclozotan has been investigated for the treatment of Parkinson's Disease.
Investigational
Experimental
AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131...
Investigational
Matched Description: … is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and
Experimental
Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
Investigational
Displaying drugs 14351 - 14375 of 14939 in total